eISSN: 2084-9834
ISSN: 0034-6233
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

vol. 57
Case report

Acute coronary syndrome leading to revision of a co-morbid condition in a young man with arthritis

Svitlana Smiyan
Roman Komorovsky
Nazarij Tomashchuk

2nd Department of Internal Medicine, Ivan Horbachevsky Ternopil National Medical University, Ukraine
Department of Cardiac Surgery, Lviv Regional Hospital, Ukraine
Reumatologia 2019; 57, 4: 243-248
Online publish date: 2019/08/31
Article file
- Acute coronary.pdf  [0.23 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Acute coronary syndrome (ACS) in young adults (aged ≤ 35 years), although relatively rare, almost always represents a diagnostic challenge as young patients, as compared with older ones, have broader etiology, other cardiovascular risk factors, and different clinical manifestations and outcomes [1, 2]. Although early atheromatous coronary artery disease remains one of the major causes of ACS in a young population [3], other important etiologies comprise non-atheromatous coronary artery disease (congenital coronary anomalies, small and medium vessel vasculitides/vasculitic syndromes, spontaneous dissections, myocardial bridging), hypercoagulable states (antiphospholipid syndrome – APLS, factor V Leiden mutation and other thrombophilias), substance abuse (recreational drug use, particularly cocaine and amphetamines, alcohol binge drinking) [4, 5].

In this context, patients with rheumatologic disorders represent a special risk group [6], typically combining multiple risk factors (vasculitis, secondary APLS [7], early [8] and accelerated [9] development of atheromatous lesions). The risk of coronary involvement in rheumatologic diseases depends on the clinical entity of the latter. For instance, in rheumatoid arthritis (RA), which is one of the most prevalent inflammatory rheumatologic disorders, as well as in ankylosing spondyloarthritis, it is relatively low as compared with primary systemic vasculitides or systemic lupus erythematosus (SLE) [10].

Case report

A 26-year-old man presented in October 2016 to our rheumatology clinic because of non-erosive polyarthritis with severely elevated acute phase reactants (erythrocyte sedimentation rate 73 mm/h, reference value: < 15 mm/h; C-reactive protein 25 mg/l, reference value: < 5 mg/l). This was preceded by a 2-year history of follow-up outside our clinic for “rheumatoid arthritis” (Table I), as well as a recent acute coronary syndrome (presumably, a myocardial infarction) (Fig. 1) due to multivessel coronary artery disease (Figs. 2 and 3) managed with coronary artery bypass grafting (CABG). At the surgeon’s discretion, it was decided to use venous grafts, and not the left internal mammary artery, as the latter showed decreased pulsation (retrospectively this was attributed to manifestation of vasculitis). The patient’s height was 170 cm, weight 55 kg, giving him a body mass index of 19 kg/m2.

Table I


Late 2014The patient first experienced pain in knee joints
Early 2015The patient started experiencing morning joint stiffness, swollen hands, dyspnea, gradual weight loss (~15 kg within 1 year). Rheumatoid arthritis was suspected and the patient initiated non-steroidal anti-inflammatory drug treatment with a positive effect
January 2016Hospitalization due to severe anemia
February 2016The patient was experiencing persistent arthralgias, subfebrile body temperature, and hair loss. Continuous therapy with corticosteroids and non-steroidal anti-inflammatory drugs was initiated
1–2 March 2016Repeated attacks of substernal chest pain at rest radiating to both arms, accompanied by fatigue and diaphoresis. The patient did not seek medical care
3 March 2016The patient presented to a local hospital. His ECG revealed T-wave inversion in anterior chest leads (Fig. 1), echocardiography demonstrated multiple segmental wall motion abnormalities with depressed systolic function (LVEF 35%), and coronary angiography detected a multivessel coronary artery disease (Fig. 2). The patient was medically stabilized
17 March 2016Coronary artery bypass grafting: SVG-OM, SVG-LAD, SVG-DA
October 2016The diagnosis of “rheumatoid arthritis” was revised in favor of “systemic lupus erythematosus”
February 2019Last follow-up. The patient is being followed up yearly in an outpatient clinic. His left ventricular systolic function has improved (LVEF 50%). The patient is receiving DMARDs and has been in remission for the past 2 years

[i] DA – diagonal artery, DMARDs – disease-modifying antirheumatic drugs, ECG – electrocardiogram, LAD – left anterior descending artery, LVEF – left ventricular ejection fraction, OM – obtuse marginal artery, SVG – saphenous vein graft.

Fig. 1

Twelve-lead electrocardiogram demonstrating ST-elevation and deep inverted T-waves in anterior chest leads consistent with recent myocardial infarction.

Fig. 2

Right anterior oblique view of the left coronary artery showing occluded (1) first obtuse marginal artery and (2) left anterior descending artery with retrograde collateral supply, and (3) critical stenosis of the diagonal branch.

Fig. 3

Right anterior oblique view of the right coronary artery showing a diffusely narrowed right coronary artery providing collateral supply to distal left anterior descending artery.


The described patient did not have any classical cardiovascular risk factors. Additional laboratory investigation showed the presence of anemia, leukopenia 3,000/μl, lymphopenia 1,000/μl, thrombocytopenia 140 K/μl, negative rheumatoid factor (< 10 IU/ml, reference value: < 14 IU/ml), negative A-CCP IgG (< 7 IU/ml, reference value: < 17 IU/ml), positive antinuclear antibodies test (ANA AAB 4.7 IU/ml, reference value: < 1 IU/ml), positive anti-double stranded DNA test (ANA-dsDNA IgG 38 IU/ml, reference value: < 14 IU/ml), positive anticardiolipin antibodies (IgA 3.12 IU/ml, reference value: < 1 IU/ml; IgG 4.28 IU/ml, reference value: < 1 IU/ml; IgM 8.07 IU/ml, reference value: < 1 IU/ml), positive extractable nuclear antigen antibodies (ENA AAB 2.9 IU/ml, reference value: < 1 IU/ml), positive anti-SSA (Ro) 1 : 100 (reference value: < 1 : 50), anti-SSB (La) 1 : 100 (reference value: < 1:50). Detailed history taking revealed the fact of photosensitivity.

Thus, the patient met the classification criteria for SLE according to the 1997 Update of the 1982 American College of Rheumatology (ACR) Revised Criteria [11] by having 5 criteria (photosensitivity, polyarthritis, hematologic disorders, immunologic disorders, positive antinuclear antibodies) while ≥ 4 criteria are required for the diagnosis.

He also met the Systemic Lupus International Collaborating Clinics (SLICC) [12] classification criteria by having 6 criteria (clinical criteria: photosensitivity, synovitis in ≥ 2 joints, leukopenia; immunologic criteria: positive ANA, anti-DNA, antiphospholipid antibodies) while ≥ 4 criteria, including at least 1 clinical and 1 laboratory criterion, are required. The patient also scored 23 points according to the new ACR/EULAR (European League Against Rheumatism) classification criteria for SLE [13] (Table II). Systemic lupus erythematosus activity index (SLEDAI) score was 18 (arthritis = 4, increased DNA binding = 2, thrombocytopenia = 1, leukopenia = 1, alopecia = 2, vasculitis = 8). This necessitated reassessment of the previous diagnosis of RA, and diagnosis of the patient with SLE and secondary APLS.

Table II

New 2018 ACR and EULAR criteria for classification of systemic lupus erythematosus [13]

Clinical domainsPointsImmunologic domainsPoints
Constitutional domainAntiphospholipid antibody domain
 Fever2 Anticardiolipin IgG > 40 GPL or anti-β2GP1 IgG > 40 U or lupus anticoagulant2
Cutaneous domain
 Non-scarring alopecia2
 Oral ulcers2Complement proteins domain
 Subacute cutaneous or discoid lupus4 Low C3 or low C43
 Acute cutaneous lupus6 Low C3 and low C44
Arthritis domainHighly specific antibodies domain
Synovitis in at least two joints or tenderness in at least two joints, and at least 30 min of morning stiffness6 Anti-dsDNA antibody
Anti-Smith antibody
Neurologic domain
Serositis domain
 Pleural or pericardial effusion5
 Acute pericarditis6
Hematologic domain
 Autoimmune hemolysis4
Renal domain
 Proteinuria > 0.5 g/24 h4
 Class II or V lupus nephritis8
 Class III or IV lupus nephritis10

[i] The criteria marked in bold were detected in the patient. 2018 ACR/EULAR score ≥ 10 = systemic lupus erythematosus; patient’s score = 23.

Patient management and follow-up

The diagnosis of SLE and subsequent administration of disease-modifying anti-rheumatic drugs, including hydroxychloroquine, systemic glucocorticoids and methotrexate according to current recommendations [14] along with anticoagulation with warfarin and low-dose acetyl salicylic acid, resulted in drug-induced remission (SLEDAI score 2 [alopecia]) and freedom from major adverse cardiac events that has been maintained for the past 2 years. According to our judgment, previous therapy which the patient was receiving for RA was limited by the presence of anemia, and therefore adequate reduction of the disease activity at that time was not achieved.


Systemic lupus erythematosus is a chronic autoimmune disease characterized by multisystem involvement. Any part of the heart may be affected, manifesting as myocarditis, pericarditis, conduction defects, valvular disease, or coronary thrombosis. Some patients also develop pulmonary hypertension. The pathogenesis of these variable manifestations is complex and still not completely understood [6, 15, 16]. With regard to the coronary artery disease, most of the available literature sources either focus on atherosclerotic process or do not contain information on the nature of coronary involvement [8, 9, 17].

Although traditional cardiovascular risk factors do not fully explain the increased cardiovascular risk in SLE, the elevated risk of ACS in these patients is considered to be associated with obesity, dyslipidemia, arterial hypertension, type 2 diabetes mellitus, sedentary lifestyle, male gender, smoking, advanced age, hyperhomocysteinemia, renal dysfunction, family history of coronary heart disease, as well as with the disease activity and presence of antiphospholipid antibodies. Antiphospholipid syndrome is associated with the incidence of myocardial infarction and angina pectoris of 5.5% and 2.7%, respectively, and the incidence of coronary heart disease is relatively not high if compared with the incidence of cerebral and/or deep vein thromboses [18]. Acute coronary syndrome is an important complication in young patients with primary APLS without coronary heart disease risk factors, as well as in patients with SLE and secondary APLS. In some patients ACS/myocardial infarction developed before or shortly after the diagnosis of SLE [19, 20].

The relative roles of coronary thrombosis and of coronary atherosclerosis in patients with APLS and/or SLE have not yet been thoroughly studied [21]. On the other hand, the issue of percutaneous coronary interventions (PCI) and CABG in patients with SLE and ACS needs further assessment because of equivocal data with regard to their appropriateness and effectiveness and increased associated risks [22].

The present case report highlights the difficulty of diagnosing SLE in a 26-year-old man who had been followed up by different specialists with a working diagnosis of seronegative “rheumatoid arthritis”. Following the ACS, the patient’s history and laboratory findings required a further detailed analysis. Attention was drawn by significant hematologic disorders (anemia, leukopenia, lymphopenia, thrombocytopenia) and a history of photosensitivity. The first manifestation of SLE in this patient was persistent non-erosive polyarthritis with highly elevated acute phase reactants, and subsequently vasculitis (coronaritis) caused symptomatic multivessel coronary artery involvement requiring CABG.

From another standpoint, the patient did meet the ACR classification criteria for RA [23] (Table III). However, no consideration was given to alternative causes of arthritis in the light of hematological manifestations and a history of photosensitivity. Also, this case serves an example that especially in seronegative arthritis, which may formally fit the classification criteria of RA, the diagnosis of RA should be supported by imaging studies. Although younger age at disease onset and short disease duration have been associated with non-erosive RA in large cohort studies [24], a non-erosive disease associated with other extra-articular symptoms should raise the suspicion of SLE [25].

Table III

2010 ACR/EULAR classification criteria for rheumatoid arthritis [23]

Joint distribution (0–5)
 1 large joint0
 2–10 large joints1
 1–3 small joints (large joints not counted)2
 4–10 small joints (large joints not counted)3
 > 10 joints (at least one small joint)5
Serology (0–3)
 Negative RF and negative ACPA0
 Low positive RF or low positive ACPA2
 High positive RF or high positive ACPA3
Symptom duration (0–1)
 < 6 weeks0
 ≥ 6 weeks1
Acute phase reactants (0–1)
 Normal CRP and normal ESR0
 Abnormal CRP or abnormal ESR1

[i] RF – rheumatoid factor, ACPA – anti-citrullinated protein antibodies, CRR – C-reactive protein, ESR – erythrocyte sedimentation rate. The criteria marked in bold were detected in the patient. 2010 ACR/EULAR score ≥ 6 = definite rheumatoid arthritis; patient’s score = 7, leading to misclassification of the patient.

Indeed, rheumatic diseases are frequently characterized by multiple and variable manifestations, and classification criteria of these disorders have been primarily developed to identify homogeneous cohorts for clinical research [26]. Although the classification criteria are widely used in routine clinical practice for diagnostic purposes, the clinical diagnosis of many rheumatic diseases with multisystem involvement, including SLE, is still largely at the discretion of the attending physician.

The present case has some limitation because the diagnosis of coronary vasculitis was made based only on the clinical presentation without histopathological examination of the affected vessel being performed. Therefore, one cannot rule out another background of coronary artery involvement, e.g., APLS and premature accelerated atherosclerosis.


The present case illustrates how early onset of ACS and subsequently multivessel coronary artery disease led to revision of the previous diagnosis of concomitant RA, and finally allowed the diagnosis of SLE to be established. In young patients with ACS and without any classical cardiovascular risk factors, another underlying etiology of vessel involvement such as systemic connective tissue disease should be considered. In such cases the indications for interventional strategy should be carefully discussed in terms of risks and benefits. If early RA is diagnosed according to classification criteria, other causes of arthritis should be excluded in patients with extra-articular manifestations (i.e., leukopenia, lymphopenia, thrombocytopenia, anemia).


[4] Conflicts of interest The authors declare no conflict of interest.



Davidson L, Wilcox J, Kim D, et al. , authors. Clinical features of precocious acute coronary syndrome. Am J Med. 2014. 127:p. 140–144


Tini G, Proietti G, Casenghi M, et al. , authors. Long-term outcome of acute coronary syndromes in young patients. High Blood Press Cardiovasc Res. 2017. 24:p. 77–84


Schoeneberger AW, Radovanovic D, Stauffer J-C, et al. , authors. Acute coronary syndromes in young patients: presentation, treatment and outcome. Int J Cardiol. 2011. 148:p. 300–304


Egred M, Viswanathan G, Davis GK , authors. Myocardial infarction in young adults. Postgrad Med J. 2005. 81:p. 741–745


Kane GC, Keogh KA , authors. Involvement of the heart by small and medium vessel vasculitis. Curr Opin Rheumatol. 2009. 21:p. 29–34


Chappuis S, Vogt P, Petitpierre S, et al. , authors. Atteintes cardiaques dans les connectivites: l’exemple du lupus érythémateux systémique. Rev Med Suisse. 2010. 6:p. 804–811


Capilla-Geay E, Poyet R, Brocq FX, et al. , authors. Infarctus du myocarde antérieur inaugural rélévateur d’un syndrome des antiphospholipides dans le cadre d’une polyarthrite lupique. Rev Med Interne. 2016. 35:p. 371–374


Mattu A, Petrini J, Swencki S, et al. , authors. Premature atherosclerosis and acute coronary syndrome in systemic lupus erythematosus. Am J Emerg Med. 2005. 23:p. 696–703


Slimani N, Hakem D, Benoui Z, et al. , authors. Infarctus du myocarde et lupus érythémateux systémique: expression d’une athérosclérose accélérée. Angéiologie. 2014. 65/66:p. 72–75


Specker C , author. Das Herz bei rheumatologischen Erkrankungen. Internist. 2007. 48:p. 284–289


Hochberg MC , author. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997. 40:p. 1725


Petri M, Orbai AM, Alarcón GS, et al. , authors. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012. 64:p. 2677–2686


Aringer M, Costenbader K, Brinks R, et al. , authors. OP0020 Validation of new systemic lupus erythematosus classification criteria. Ann Rheum Dis. 2018. 77:p. 60


Mosca M, Tani C, Aringer M, et al. , authors. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010. 69:p. 1269–1274


Miner JJ, Kim AH , authors. Cardiac manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am. 2014. 40:p. 51–60


Liu Y, Kaplan MJ , authors. Cardiovascular disease in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018. 30:p. 441–448


Kay SD, Poulsen MK, Diederichsen AC, Vosa A , authors. Coronary, carotid, and lower-extremity atherosclerosis and their relationship in Danish patients with systemic lupus erythematosus. J Rheumatol. 2016. 43:p. 315–322


Cervera R, Piette JC, Font J, et al. , authors. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002. 46:p. 1019–1027


Urowitz MB, Gladman DD, Anderson NM, et al. , authors. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Sci Med. 2016. 3:p. e000143


Doyle R, Perry JC, Brennan J, Fahey J , authors. Acute myocardial infarction as the presenting symptom of systemic lupus erythematosus. Pediatr Cardiol. 2009. 30:p. 858–861


Ito S, Hasuo T , authors. Intravascular images of coronary stenosis with multiple channels in a patient with antiphospholipid syndrome: the optical coherence tomography findings. Intern Med. 2017. 56:p. 1351–1356


Budhun PK, Boodhoo KD, Long MY, Chen MH , authors. Impact of antiphospholipid syndrome and/or systemic lupus erythematosus on the long-term adverse cardiovascular outcomes in patients after percutaneous coronary intervention. A systematic review and meta-analysis. Medicine (Baltimore). 2016. 95:p. e320


Aletaha D, Neogi T, Silman AJ, et al. , authors. 2010 rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis. 2010. 69:p. 1580–1588


Liao KP, Weinblatt ME, Cui J, et al. , authors. Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study. Rheumatology (Oxford. 2011. 50:p. 1473–1479


Amaya-Amaya J, Calixto O-J, Saade-Lemus S, et al. , authors. Does nonerosive rheumatoid arthritis exist? A cross-sectional analysis and a systematic literature review. Semin Arthritis Rheum. 2015. 44:p. 489–498


June RR, Aggarwal R , authors. The use and abuse of diagnostic/classification criteria. Best Pract Res Clin Rheumatol. 2014. 28:p. 921–934

Copyright: © 2019 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.